Magalhães, Giselle SantosGregório, Juliana FabianaRibeiro, Arthur Tonani Pereira CançadoBaroni, Isis FelippeVasconcellos, Ana Victoria de OliveiraNakashima, Gabriela PansanatoOliveira, Isabel Fusaro AguiarMatos, Natália Alves deCastro, Thalles de FreitasBezerra, Frank SilvaSinisterra, Ruben DarioPinho, VanessaTeixeira, Mauro MartinsSantos, Robson Augusto Souza dosMachado, Maria da Glória RodriguesSantos, Maria José Campagnole dos2021-11-242021-11-242021MAGALHÃES, G. S. et al. Oral formulation of Angiotensin-(1-7) promotes therapeutic actions in a model of eosinophilic and meutrophilic asthma. Frontiers in Pharmacology, v. 12, p. 1-9, mar. 2021. Disponível em: <https://www.frontiersin.org/articles/10.3389/fphar.2021.557962/full>. Acesso em: 10 jun. 2021.1663-9812http://www.repositorio.ufop.br/jspui/handle/123456789/14035The presence of eosinophils and neutrophils in the lungs of asthmatic patients is associated with the severity of the disease and resistance to corticosteroids. Thus, defective resolution of eosinophilic and neutrophilic inflammation is importantly related to exacerbation of asthma. In this study, we investigated a therapeutic action of angiotensin-(1-7) (Ang-(1-7)) in a model of asthma induced by ovalbumin (OVA) and lipopolysaccharide (LPS). Balb-c mice were sensitized and challenged with OVA. Twentythree hours after the last OVA challenge, experimental groups received LPS, and 1 h and 7 h later, mice were treated with oral formulation of Ang-(1-7). On the next day, 45 h after the last challenge with OVA, mice were subjected to a test of motor and exploratory behavior; 3 h later, lung function was evaluated, and bronchoalveolar lavage fluid (BALF) and lungs were collected. Motor and exploratory activities were lower in OVA + LPSchallenged mice. Treatment with Ang-(1-7) improved these behaviors, normalized lung function, and reduced eosinophil, neutrophil, myeloperoxidase (MPO), eosinophilic peroxidase (EPO), and ERK1/2 phosphorylation (p-ERK1/2) in the lungs. In addition, Ang-(1-7) decreased the deposition of mucus and extracellular matrix in the airways. These results extended those of previous studies by demonstrating that oral administration of Ang-(1-7) at the peak of pulmonary inflammation can be valuable for the treatment of neutrophil- and eosinophil-mediated asthma. Therefore, these findings potentially provide a new drug to reverse the natural history of the disease, unlike the current standards of care that manage the disease symptoms at best.en-USabertoResolution of inflammationAllergic lung inflammationLipopolysaccharide(LPS)Artigo publicado em periodicoThis is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. Source: The article PDF. https://doi.org/10.3389/fphar.2021.557962